Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials

Schizophrenia Research

Volumn 126, Issue 1-3, 2011, Pages 212-219

  Furukawa, Toshi A ^a,b   Akechi, Tatsuo ^b   Wagenpfeil, Stefan ^c   Leucht, Stefan ^c  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotic agents; Effect size; Evidence based medicine; Number needed to treat; Rating scale

Indexed keywords

AMISULPRIDE; HALOPERIDOL; OLANZAPINE; PLACEBO; RISPERIDONE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; ATTRIBUTABLE RISK; BRIEF PSYCHIATRIC RATING SCALE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NUMBER NEEDED TO TREAT; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPHARMACOTHERAPY; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK; RISK FACTOR; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; MALE; META-ANALYSIS AS TOPIC; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 79952002459     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.10.016     Document Type: Article

References (33)

1. 2008. Review Manager (RevMan). The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
2. Altman D.G., Royston P. The cost of dichotomising continuous variables. BMJ 2006, 332:1080.
3. Beasley C.M., Hamilton S.H., Crawford A.M., Dellva M.A., Tollefson G.D., Tran P.V., Blin O., Beuzen J.N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol. 1997, 7:125-137.
4. Beasley C.M., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl.) 1996, 124:159-167.
5. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996, 14:111-123.
6. Carriere P., Bonhomme D., Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur. Psychiatry 2000, 15:321-329.
7. Colonna L., Saleem P., Dondey-Nouvel L., Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int. Clin. Psychopharmacol. 2000, 15:13-22.
8. Deeks J.J. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat. Med. 2002, 21:1575-1600.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
10. Duggan L., Fenton M., Rathbone J., Dardennes R., El-Dosoky A., Indran S. Olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2005, CD001359.
11. Furukawa T.A., Guyatt G.H., Griffith L.E. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int. J. Epidemiol. 2002, 31:72-76.
12. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., Birbara C., Box J., Natarajan K., Nuamah I., Li T., Aranda R., Hagerty D.T., Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J. Med. 2005, 353:1114-1123.
13. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
14. Johnson N.L., Welch B.L. Application of the non-central t-distribution. Biometrika 1939, 31:362-389.
15. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
16. Keefe R.S., Young C.A., Rock S.L., Purdon S.E., Gold J.M., Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. 2006, 81:1-15.
17. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., Li S., Dooley L.T., Gordon K.B. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
18. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
19. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32:1903-1910.
20. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatry 2005, 187:366-371.
21. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. 2005, 79:231-238.
22. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 2003, 160:1396-1404.
23. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst. 1959, 22:719-748.
24. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 1994, 151:825-835.
25. Moller H.J., Boyer P., Fleurot O., Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl.) 1997, 132:396-401.
26. Norman G.R., Sridhar F.G., Guyatt G.H., Walter S.D. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med. Care 2001, 39:1039-1047.
27. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
28. Peuskens J., Link C.G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. 1997, 96:265-273.
29. Puech A., Fleurot O., Rein W. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr. Scand. 1998, 98:65-72.
30. Sackett D.L. Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!). CMAJ 2001, 165:1226-1237.
31. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., Link C.G. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry 1997, 54:549-557.
32. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 1997, 154:457-465.
33. Waraich P.S., Adams C.E., Roque M., Hamill K.M., Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst. Rev. 2002, CD001951.